Biophan Technologies Inc. (Symbol: BIPH) develops technologies designed to make biomedical devices safe and image compatible with the magnetic resonance imaging (MRI) environment. They also develop surgical devices suc as catheters and guidewires, implanted medical systems such as pacemakers, and other devices such as stents to be safely and effectively imaged under MRI. Currently Biophan and its licensors hold a total of 144 US patents, licenses, or applications.

They recently just acquired MYOTECH, LLC - who is currently developing the first generation of MYO-VAD, a device designed to quickly restore cardiac output in patients suffering from many forms of heart failure (Read here). They velieve that the MYO-VAD devices has a great potential to generate $100 million in annual revenue for Biophan in approximately five years (Heh..Not too bad!)

Their outline of technological and financial strategy was recently published on Medical Technology Business Europe (Read here) - which I think you have to read before deciding whether to invest your money in this company or not.

Currently, they’re traded at $1.59/share. Their were once traded as high as $3.50/share. Judging from how crazy they fluctuate within the past 12 months, I’ll have to say they’re only good as a long-term investment.

Their technologies are still in testing phase. They haven’t started selling their products yet (so don’t expect to see their price/share go up through the roof anytime soon). However, if you want to invest in them, right now is definitely a good time to invest.

Recently, I’ve started paying more attention to bio-tech stocks. I realized that most of these biotech companies are not making a lot of money (yet) since most of them are still trying to perfect their technologies. I guess for the next few postings, you can expect to see a lot about the bio-tech companies

Quote of the Day:
If you can run one business well, you can run any business well. - Richard Branson